This HTML5 document contains 60 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n13http://linked.opendata.cz/resource/drugbank/drug/DB01074/identifier/pubchem-substance/
n14http://linked.opendata.cz/resource/drugbank/drug/DB01074/identifier/drugbank/
n4http://linked.opendata.cz/resource/mesh/concept/
n11http://bio2rdf.org/drugbank:
n9http://linked.opendata.cz/resource/drugbank/drug/DB01074/identifier/chemspider/
admshttp://www.w3.org/ns/adms#
n8http://linked.opendata.cz/resource/drugbank/drug/DB01074/identifier/chebi/
n17http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/ontology/drugbank/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/mesh/
n20http://linked.opendata.cz/resource/drugbank/drug/DB01074/identifier/wikipedia/
n19http://linked.opendata.cz/resource/drugbank/drug/DB01074/identifier/pharmgkb/
n6http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n12http://linked.opendata.cz/resource/drugbank/drug/DB01074/identifier/pubchem-compound/
n16http://linked.opendata.cz/resource/atc/
n15http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01074
rdf:type
n5:Drug
n5:description
2-(2,2-Dicyclohexylethyl)piperidine. Coronary vasodilator used especially for angina of effort. It may cause neuropathy and hepatitis. [PubChem]
n5:group
approved
n5:halfLife
Variable and non-linear. Some reports show a half-life of 2-6 days, others indicate it could be as high as 30 days.
n5:indication
For the management of severe angina pectoris.
owl:sameAs
n11:DB01074 n17:DB01074
dcterms:title
Perhexiline
adms:identifier
n8:35553 n9:4584 n12:4746 n13:46504471 n14:DB01074 n19:PA130150436 n20:Perhexiline
n5:mechanismOfAction
Perhexiline binds to the mitochondrial enzyme carnitine palmitoyltransferase (CPT)-1 and CPT-2. It acts by shifting myocardial substrate utilisation from long chain fatty acids to carbohydrates through inhibition of CPT-1 and, to a lesser extent, CPT-2, resulting in increased glucose and lactate utilization. This results in increased ATP production for the same O2 consumption as before and consequently increases myocardial efficiency.
n5:synonym
(-)-2-(2,2-Dicyclohexylethyl)piperidine Perhexilinum Perhexilline 2-(2,2-Dicyclohexylethyl)piperidine Perhexilina Perhexilene (+)-2-(2,2-Dicyclohexylethyl)piperidine Perhexiline
n5:toxicity
Oral LD<sub>50</sub> rat: 2150 mg/kg; Oral LD<sub>50</sub> Mouse: 2641 mg/kg. Short term adverse effects include nausea, transient dizziness, hypoglycaemia in diabetic patients, and torsade de pointes (rare).
n5:proteinBinding
Perhexiline and its metabolites are highly protein bound (>90%).
n5:synthesisReference
Stephen W. Horgan, Frank P. Palopoli, Edward J. Schwoegler, "Process for preparing 2-(2,2-dicyclohexylethyl)piperidine." U.S. Patent US4069222, issued August, 1950.
n3:hasConcept
n4:M0016281
n5:IUPAC-Name
n6:271B6068-363D-11E5-9242-09173F13E4C5
n5:InChI
n6:271B606E-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n6:271B606D-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n6:271B606A-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n6:271B606B-363D-11E5-9242-09173F13E4C5
n5:SMILES
n6:271B606C-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n6:271B6066-363D-11E5-9242-09173F13E4C5 n6:271B607D-363D-11E5-9242-09173F13E4C5
n5:logP
n6:271B607E-363D-11E5-9242-09173F13E4C5 n6:271B6064-363D-11E5-9242-09173F13E4C5 n6:271B6067-363D-11E5-9242-09173F13E4C5
n5:logS
n6:271B6065-363D-11E5-9242-09173F13E4C5
n15:hasATCCode
n16:C08EX02
n5:H-Bond-Acceptor-Count
n6:271B6074-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n6:271B6075-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n6:271B606F-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n6:271B6070-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n6:271B6072-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n6:271B6071-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n6:271B6073-363D-11E5-9242-09173F13E4C5
n5:absorption
Well absorbed (>80%) from the gastrointestinal tract following oral administration.
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
6621-47-2
n5:category
n5:Bioavailability
n6:271B6079-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n6:271B607B-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n6:271B607C-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n6:271B6078-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n6:271B6077-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n6:271B607A-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n6:271B6069-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n6:271B6076-363D-11E5-9242-09173F13E4C5